Stereotaxis, Inc. STXS
We take great care to ensure that the data presented and summarized in this overview for Stereotaxis, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STXS
View all-
Dafna Capital Management LLC Los Angeles, CA13.7MShares$28 Million7.17% of portfolio
-
Lagoda Investment Management, L.P. New York, NY3.83MShares$7.85 Million4.5% of portfolio
-
Black Rock Inc. New York, NY3.54MShares$7.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$6.34 Million0.0% of portfolio
-
Arbiter Partners Capital Management LLC New York, NY2.79MShares$5.72 Million6.12% of portfolio
-
Redmile Group, LLC San Francisco, CA2.11MShares$4.32 Million0.28% of portfolio
-
Essex Investment Management CO LLC Boston, MA1.41MShares$2.89 Million0.54% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$2.85 Million0.0% of portfolio
-
Archon Capital Management LLC Seattle, WA1.28MShares$2.63 Million5.19% of portfolio
-
Prescott Group Capital Management, L.L.C. Tulsa, OK824KShares$1.69 Million0.27% of portfolio
Latest Institutional Activity in STXS
Top Purchases
Top Sells
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Insider Transactions at STXS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 20
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
442
+0.02%
|
$442
$1.88 P/Share
|
Aug 19
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
812
+0.03%
|
$812
$1.88 P/Share
|
Aug 15
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
8,095
+0.29%
|
$8,095
$1.9 P/Share
|
Jul 01
2024
|
Nathan Fischel Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,475
+9.16%
|
-
|
Jul 01
2024
|
David Benfer Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,475
+12.66%
|
-
|
Jul 01
2024
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,475
+17.92%
|
-
|
Jul 01
2024
|
Arun Swarup Menawat Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,475
+5.95%
|
-
|
Jul 01
2024
|
Ross B Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,475
+11.04%
|
-
|
Jun 14
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
7,000
+0.25%
|
$7,000
$1.86 P/Share
|
May 31
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.04%
|
$1,000
$1.96 P/Share
|
May 29
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
3,026
+0.11%
|
$3,026
$1.9 P/Share
|
May 28
2024
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
6,000
+0.22%
|
$6,000
$1.91 P/Share
|
Jan 02
2024
|
Arun Swarup Menawat Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+7.58%
|
-
|
Jan 02
2024
|
Ross B Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+14.67%
|
-
|
Jan 02
2024
|
David Benfer Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+17.08%
|
-
|
Jan 02
2024
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+25.33%
|
-
|
Jan 02
2024
|
Robert J Messey Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+11.13%
|
-
|
Jan 02
2024
|
Nathan Fischel Director |
BUY
Grant, award, or other acquisition
|
Direct |
64,935
+11.98%
|
-
|
Dec 15
2023
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
11,060
+0.4%
|
$11,060
$1.72 P/Share
|
Nov 30
2023
|
Paul J Isaac Director |
BUY
Open market or private purchase
|
Indirect |
2,808
+0.1%
|
$2,808
$1.56 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 657K shares |
---|---|
Open market or private purchase | 103K shares |